303 related articles for article (PubMed ID: 26256007)
1. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.
Sneider B; Pristed SG; Correll CU; Nielsen J
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1669-76. PubMed ID: 26256007
[TBL] [Abstract][Full Text] [Related]
2. Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A Nation-wide pharmacoepidemiological study.
Pristed SG; Correll CU; Nielsen J
Psychiatry Res; 2017 Sep; 255():198-203. PubMed ID: 28578178
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China.
Hou CL; Ma XR; Zang Y; Jia FJ; Lin YQ; Chiu HF; Ungvari GS; Ng CH; Zhong BL; Cao XL; Li Y; Cai MY; Xiang YT
Int J Clin Pharmacol Ther; 2016 Jan; 54(1):36-42. PubMed ID: 26521927
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.
Wu YH; Lai CY; Chang YS
Psychogeriatrics; 2015 Mar; 15(1):7-13. PubMed ID: 25515355
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.
Li Q; Xiang YT; Su YA; Shu L; Yu X; Chiu HF; Correll CU; Ungvari GS; Lai KY; Ma C; Wang GH; Bai PS; Li T; Sun LZ; Shi JG; Chen XS; Mei QY; Li KQ; Si TM
Aust N Z J Psychiatry; 2015 Feb; 49(2):129-36. PubMed ID: 24923760
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.
Ayenew W; Asmamaw G; Bitew T
Int J Neuropsychopharmacol; 2021 Dec; 24(12):956-964. PubMed ID: 34245271
[TBL] [Abstract][Full Text] [Related]
7. A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.
Gaviria AM; Franco JG; Aguado V; Rico G; Labad J; de Pablo J; Vilella E
PLoS One; 2015; 10(10):e0139403. PubMed ID: 26427051
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and correlates of antipsychotic polypharmacy in Hong Kong.
Lung SLM; Lee HME; Chen YHE; Chan KWS; Chang WC; Hui LMC
Asian J Psychiatr; 2018 Mar; 33():113-120. PubMed ID: 29574303
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and predictors of long-term institutionalization in patients with schizophrenia.
Uggerby P; Nielsen RE; Correll CU; Nielsen J
Schizophr Res; 2011 Sep; 131(1-3):120-6. PubMed ID: 21458239
[TBL] [Abstract][Full Text] [Related]
10. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis.
Sørensen HJ; Jensen SO; Nielsen J
Eur Neuropsychopharmacol; 2013 Aug; 23(8):872-8. PubMed ID: 23642346
[TBL] [Abstract][Full Text] [Related]
11. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service.
John AP; Gee T; Alexander S; Ramankutty P; Dragovic M
Australas Psychiatry; 2014 Dec; 22(6):546-50. PubMed ID: 25147317
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH
J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.
Gallego JA; Bonetti J; Zhang J; Kane JM; Correll CU
Schizophr Res; 2012 Jun; 138(1):18-28. PubMed ID: 22534420
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.
Correll CU; Gallego JA
Psychiatr Clin North Am; 2012 Sep; 35(3):661-81. PubMed ID: 22929872
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).
Xiang YT; Wang CY; Si TM; Lee EH; He YL; Ungvari GS; Chiu HF; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong KH; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N
Pharmacopsychiatry; 2012 Jan; 45(1):7-12. PubMed ID: 21989602
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy.
Kristensen D; Hageman I; Bauer J; Jørgensen MB; Correll CU
J ECT; 2013 Dec; 29(4):271-6. PubMed ID: 23859980
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.
Armstrong KS; Temmingh H
Braz J Psychiatry; 2017; 39(4):293-301. PubMed ID: 28177063
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
